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Fusaric acid (FA), a mycotoxin produced by the Fusarium species, is a common contaminant of 
maize and other agricultural products. FA is known to mediate toxicity in plants and animals; 
however, its mechanism of action is unknown. p53 is a tumour suppressor protein that is 
activated in response to cellular stress. Key functions of p53 include cell growth arrest, 
senescence and apoptosis. The function of p53 is regulated by a variety of post-translational 
modifications such as ubiquitination, phosphorylation and acetylation. p53 is ubiquitinated by 
the protein murine double minute 2 (MDM2) and degraded in the absence of cellular stress. The 
phosphorylation and acetylation of p53 occur during cellular stress and increase p53 stability 
and activity. The acetylation of p53 is regulated by histone acetyltransferases, CBP/p300, and 
histone deacetylases, HDAC1 and Sirt1. This study investigated the effect of FA on DNA 
integrity and the post-translational modifications of p53 in hepatocellular carcinoma (HepG2) 
cells. Methods included: (i) culture and treatment of HepG2 cells (IC50: 104µg/ml FA, 24hrs); 
(ii) comet assay (DNA damage); (iii) western blot (protein expression of p53, phosphorylated-
Ser15-p53 (p-Ser15-p53), acetylated-K382-p53 (a-K382-p53), acetyl-CBP (K1535)/p300 
(K1499) (a-CBP (K1535)/p300 (K1499)), HDAC1, phosphorylated-Ser47-Sirt1 (p-Ser47-Sirt1) 
and MDM2); and (v) Hoechst 33342 assay (cell cycle and apoptosis analysis). FA caused DNA 
damage (89.98 ± 10.36µm vs. 33.99 ± 6.76µm, p<0.0001) in HepG2 cells relative to the control. 
FA significantly increased the protein expression of p-Ser15-p53 (9.76-fold, p=0.0002), a-
K382-p53 (1.75-fold, p=0.0329), p-Ser47-Sirt1 (1.24-fold, p=0.0127) and MDM2 (5.63-fold, 
p=0.0094) in HepG2 cells. The expression of p53 (0.73-fold, p=0.0034), a-CBP (K1535)/p300 
(K1499) (0.58-fold, p=0.0043) and HDAC1 (0.84-fold, p=0.0006) were significantly decreased 
in the FA treated cells. Hoechst analysis of HepG2 cells showed that FA inhibited cell 
proliferation and induced apoptosis as evident by the absence of dividing cells and the presence 
of apoptotic bodies. FA is a genotoxic agent that increased p-Ser15-p53, decreased the 
interaction between MDM2 and p53 and increased the interaction between p53 and a-
CBP/p300. This increased the acetylation of p53 (further achieved by the down-regulation of 







Mycotoxin contamination of foods and feeds is a serious problem occurring worldwide 
(Milićević et al., 2010). Areas most often affected by mycotoxins include developing countries 
and poverty stricken areas where malnutrition is a major concern and the consumption of 
mycotoxin contaminated foods form a staple diet for many people (Bennett and Klich, 2003). 
The application of modern agricultural practices as well as regular government screening helps 
lower the risk of exposure to mycotoxins; however, it does not completely eliminate it. Hence, 
mycotoxin contamination is a recurring problem (Wild and Gong, 2010). 
Mycotoxins are low molecular weight natural compounds produced as secondary metabolites of 
toxigenic moulds (Bennett and Klich, 2003, Milićević et al., 2010). Mycotoxins are common 
contaminants of a wide variety of foods and feeds and the consumption of mycotoxin 
contaminated foods may have a serious impact on human and animal health (Bennett and Klich, 
2003, Milićević et al., 2010, Peraica et al., 1999, Zain, 2011). Several mycotoxins have been 
identified; many of which are carcinogenic, mutagenic, nephrotoxic, hepatotoxic and neurotoxic 
(Milićević et al., 2010, Peraica et al., 1999). Exposure to mycotoxins can occur via ingestion, 
inhalation and dermal routes leading to several diseases known as mycotoxicoses (Bennett and 
Klich, 2003, Milićević et al., 2010, Peraica et al., 1999, Zain, 2011).  
The Fusarium species are a group of diverse and adaptable fungi that colonise plants causing 
diseases on agricultural crops with major economic losses (Bouarab, 2009). Fusaric acid (FA) 
also known as 5-butylpicolinic acid is a secondary metabolite and mycotoxin produced by the 
Fusarium species (Bacon et al., 1996, Fairchild et al., 2005). Fusaric acid is a fusariotoxin 
commonly found in maize and other cereal grains, which form an essential part of human food 
and animal feeds (Milićević et al., 2010). Therefore, the consumption of FA contaminated 
commodities may have adverse effects in humans and animals. 
Fusaric acid is a Picolinic acid derivative and well-known metal chelating agent. The structure 
of FA is similar to that of Picolinic acid in that it contains the well conserved chelating structure 
of Picolinic acid as well as an additional fused aromatic ring structure or 5-butyl side chain 
(Bochner et al., 1980). Fusaric acid binds divalent cations and prevents these ions from 
functioning in biological processes (Swinburne, 2012). 
Fusaric acid is known to affect both plants (D'Alton and Etherton, 1984, Diniz and Oliveira, 




Terasawa and Kameyama, 1971). However, little is known on the mechanism by which FA 
exerts its toxic effects. Previous studies have shown FA to cause changes in membrane 
permeability (D'Alton and Etherton, 1984), dysfunctions in mitochondrial activity (Abdul et al., 
2016, Diniz and Oliveira, 2009), inhibition of respiration (D'Alton and Etherton, 1984, 
Pavlovkin et al., 2004, Telles-Pupulin et al., 1996) and ultimately cell death (Abdul et al., 2016, 
Stack et al., 2004). Fusaric acid is also known to have anti-hypertensive (Hidaka et al., 1969, 
Terasawa and Kameyama, 1971) and anti-tumour effects (Stack et al., 2004). Synergistic effects 
of FA with other mycotoxins produced by the Fusarium species such as Fumonisin B1, 
deoxynivalenol (DON) and diacetoxyscirpenol (DAS) have also been reported (Bacon et al., 
1995, Bungo et al., 1999, Fairchild et al., 2005, Ogunbo et al., 2007, Voss et al., 1999).  
p53, often referred to as the guardian of the genome, is a tumour suppressor protein and 
transcription factor that is activated in response to cellular stress (Prives and Hall, 1999). 
Several stressors can activate p53 such as DNA damage, excessive oncogene activation, 
hypoxia and oxidative stress (Prives and Hall, 1999). Once activated, p53 mediates a plethora of 
functions including cell growth arrest, DNA repair, senescence and apoptosis (Barlev et al., 
2001, Brooks and Gu, 2003, George, 2011, Reed and Quelle, 2014, Zhang et al., 2015). The 
function of p53 is regulated by a variety of post-translational modifications (van Leeuwen et al., 
2013). These modifications include ubiquitination, phosphorylation and acetylation (Barlev et 
al., 2001, Brooks and Gu, 2003, Reed and Quelle, 2014, van Leeuwen et al., 2013, Zhang et al., 
2015).  
The ubiquitination of p53 occurs in the absence of cellular stress and is mediated by the protein 
murine double minute 2 (MDM2) (Dai and Gu, 2010, Brooks and Gu, 2003). MDM2 is the 
predominant negative regulator of p53 (Brooks and Gu, 2003). It adds ubiquitin chains to the C-
terminal lysine residues targeting p53 for degradation by the 26S proteasome (Brooks and Gu, 
2003, Dai and Gu, 2010, Reed and Quelle, 2014). In this way, MDM2 helps maintain low levels 
of p53 in the absence of cellular stress. 
During DNA damage several protein kinases such as ataxia telangiectasia mutated (ATM), 
ataxia telangiectasia and Rad 3 related (ATR) and DNA-dependent protein kinase (DNA-PK) 
are triggered (Barlev et al., 2001, Brooks and Gu, 2003, Reed and Quelle, 2014). These protein 
kinases phosphorylate p53 on several serine and threonine residues leading to the stabilization 
of p53 (Brooks and Gu, 2003, Dai and Gu, 2010).  
p53 is also regulated by acetylation (Gu and Roeder, 1997). The acetylation of p53 occurs in 




propagation of cells with damaged DNA (Dai and Gu, 2010, Brooks and Gu, 2003, Barlev et al., 
2001, Reed and Quelle, 2014, Zhang et al., 2015). CREB-binding protein (CBP) and p300 are 
major histone acetyltransferases (HATs) involved in the acetylation of p53 whereas Sirt1 and 
HDAC1 are major deacetylases involved in the deacetylation of p53 (Zhang et al., 2015, Dai 
and Gu, 2010, Brooks and Gu, 2003). The acetylation of p53 is associated with enhanced p53 
activity (Blattner, 2008) whereas the deacetylation of p53 is associated with the inactivation of 
p53 and cell survival (Lee et al., 2012).  
 
This in vitro study investigated a possible mechanism of FA induced cytotoxicity in the 
hepatocellular carcinoma (HepG2) cell line by determining the effect of FA on DNA integrity 
and the post-translational modifications of p53 over a period of 24 hrs. It was hypothesized that 










Mycotoxins are secondary metabolites produced by moulds, mostly belonging to the genera 
Aspergillus, Penicillium and Fusarium (Yiannikouris and Jouany, 2002). These toxins are 
produced in cereal grains and animal feeds before, during and after harvests, in various 
environmental conditions (Yiannikouris and Jouany, 2002). Mycotoxins are capable of exerting 
harmful effects in humans, animals and crops and are responsible for causing illnesses and 
major economic losses (Peraica et al., 1999, Zain, 2011). The worldwide contamination of foods 
and feeds with mycotoxins is a significant problem (Zain, 2011). Aflatoxin, Fumonisins, 
Tricothecenes and Ochratoxins are the most common food contaminating mycotoxins. These 
mycotoxins are potent nephrotoxins, hepatotoxins and carcinogens that induce a wide variety of 
health problems in both humans and animals (Bennett and Klich, 2003, Peraica et al., 1999, 
Zain, 2011). 
The interest in mycotoxins was first sparked in 1960 following the outbreak of Turkey X 
disease in which approximately 100 000 turkey poults died as a result of consuming aflatoxin 
(Aspergillus flavus) contaminated peanut meal (Peraica et al., 1999, Bennett and Klich, 2003). 
Since then, a large number of mycotoxins have been discovered and several outbreaks involving 
mycotoxins have occurred and still continue to occur globally (Yiannikouris and Jouany, 2002, 
Peraica et al., 1999).  
Mycotoxins are low molecular weight natural products produced mainly by filamentous fungi 
(Bennett and Klich, 2003). Mycotoxins have no biochemical significance in the growth and 
development of the fungus and are often produced as an adaptive response to a change in the 
availability of nutrients and other environmental conditions (Zain, 2011). Mycotoxins are highly 
toxic compounds usually produced for purposes of self-defence or to dissolve cellular 
membranes as part of their fungal pathogenicity (Stack Jr et al., 2014). The chemical structures 
of mycotoxins vary considerably and account for their differences in biological effects 
(Yiannikouris and Jouany, 2002, Peraica et al., 1999). While all mycotoxins are of fungal 




concentration are both important to elicit a toxic effect (Bennett and Klich, 2003). For example, 
some fungal products such as penicillin are toxic to bacteria and are important prescribed 
antibiotics (Bennett and Klich, 2003). 
Mycotoxins are common contaminants of a wide variety of food sources. Human exposure to 
mycotoxins may result from the consumption of contaminated foods as well as the carry-over of 
mycotoxins and toxic metabolites in animal products such as milk, meat and eggs (Yiannikouris 
and Jouany, 2002, Zain, 2011). However, skin-contact with mould infested substrates and 
inhalation of spore-borne toxins are also important sources of exposure (Bennett and Klich, 
2003).  
Exposure to mycotoxins lead to several, often unrecognized, diseases known as mycotoxicoses 
(Peraica et al., 1999, Zain, 2011). Mycotoxicoses are common in areas where there are poor 
methods of food handling and improper storage of food. It also frequently occurs in countries 
such as South Africa (SA) where malnutrition is a problem and where maize and cereal grains 
form a staple diet for many people (Bennett and Klich, 2003). The severity of mycotoxicoses 
vary among individuals and are dependent on the type of mycotoxin, the dose and length of 
exposure, route of exposure as well as the health and sex of the affected individual (Bennett and 
Klich, 2003, Peraica et al., 1999). The ability of mycotoxins to act synergistically with other 
chemicals to which the individual may have been exposed is also a major determinant of 
toxicity (Peraica et al., 1999). Mycotoxicoses, like all other toxicological syndromes, can be 
categorized as acute or chronic (Bennett and Klich, 2003). Acute or short-term toxicity 
generally have a rapid onset with an obvious toxic response whereas chronic or long-term 
toxicity usually occur at low doses and have irreversible effects (Bennett and Klich, 2003).  
Mycotoxins are natural contaminants of food and therefore, their production is often inevitable. 
Several efforts to address mycotoxin exposure involve the removal of mycotoxin-contaminated 
commodities from the food supply by regular government screening. Despite efforts to control 
fungal contamination, extensive mycotoxin contamination is continuously reported in foods and 








1.2. Fusaric Acid: A Fusarium Mycotoxin 
 
The genus Fusarium comprises of over 1 000 fungal species that cause diseases on agricultural 
crops with severe economic consequences worldwide (Bouarab, 2009). The Fusarium species 
are remarkably diverse and adaptable fungi found in soils globally (Bouarab, 2009). They are 
major plant pathogens and are capable of producing a wide variety of toxic metabolites. A large 
number of plants are symptomatically and asymptomatically infected by the Fusarium species 
causing immense damage and major economic losses (Bacon et al., 1996). These fungi have 
been identified on cereal crops in Western Europe and North America; wheat, cotton and barley 
in China; and rice in Japan, Taiwan and Thailand (Bouarab, 2009); where they have been 
implicated in causing head blights, ear rot and wilting (Bouarab, 2009). 
Fusaric acid (FA ; 5-butylpicolinic acid or 5-n-butyl-pyridine-2-carboxylic acid) is a secondary 
metabolite and mycotoxin produced by several members of the Fusarium species (Fairchild et 
al., 2005). These include, among others, Fusarium moniliforme, Fusarium oxysporum and 
Fusarium heterosporum (Fairchild et al., 2005, Bacon et al., 1996). Fusaric acid is the most 
widely distributed mycotoxin produced by the Fusarium species and thus may serve as a 
presumptive indicator of Fusarium contamination in foods and feeds (Bacon et al., 1996). 
Fusaric acid is a common contaminant of maize and other cereal grains such as barley, wheat 
millets and sorghum (Figure 1.1) (Bacon et al., 1996, Voss et al., 1999, Ogunbo et al., 2007). 
Fusaric acid is an often neglected mycotoxin and surveys to determine the concentration of FA 
in feeds and other agricultural products are limited (Voss et al., 1999). The concentration of FA 
naturally occurring in foods is approximately 643µg/kg (Streit et al., 2013). However, Bacon et 
al (1996) showed that the Fusarium species are capable of producing high levels of FA, ranging 
from 20 mg/ml to 1 080 mg/ml, in autoclaved maize (Bacon et al., 1996). Another study found 
that corn and swine feeds were contaminated with up to 36 ppm FA (Smith and Sousadias, 
1993) and up to 12.4 ppm was found in toxic poultry and livestock feeds (Voss et al., 1999).   
The prevalence of mycotoxins in foods and feeds is a major focus of several studies (Darwish et 
al., 2014, Hawkins, 2013, Hawkins, 2014). A recent study determined the prevalence of 
mycotoxins in corn and other cereal grains (Hawkins, 2014). In particular, approximately 30% 
of wheat and 79% of corn were contaminated with FA (Figure 1.2) (Hawkins, 2014). This is of 
great concern as maize and cereal grains form an integral part of people’s diets and such a high 
degree of contamination increases the possibility of animal and human exposure to FA, posing a 




















1.2.1. Structure of Fusaric Acid 
 
Fusaric acid is a product of Fusarium fungal fermentation and a physiologic metabolite of 
tryptophan and Picolinic acid (Stack et al., 2004). Picolinic acid also known as 2-picolinic acid 
and 2-pyridine carboxylic acid is a six membered ring structure and isomer of nicotinic acid that 
consists of the chemical formula, C6H5O2N (Grant et al., 2009). The ability to act as a metal 
chelating agent and induce an anti-proliferative effect is one of the most widely studied 
characteristics of Picolinic acid (Fernandez-Pol et al., 1977, Grant et al., 2009). Picolinic acid is 
a bidentate metal chelating agent known to efficiently chelate copper, iron, zinc and cadmium 
(Fernandez-Pol et al., 1977, Grant et al., 2009). These metal ions are essential for the growth of 
cells and their chelation by Picolinic acid may provide a mechanism by which this compound 
exerts its anti-proliferative effect (Grant et al., 2009). A previous study conducted by 
Fernandez-Pol (1977), showed that Picolinic acid inhibits the growth of normal rat kidney 
(NRK) cells in a dose-dependent manner. This may occur by interfering with the specific metal 
requirements for cell growth and by altering NAD+ metabolism (Fernandez-Pol et al., 1977). 
Picolinic acid is a pyridine derivative that has the capacity to undergo exchange reactions with 
the nicotinamide moiety of NAD+ and thus forms NAD+ analogues (Fernandez-Pol et al., 1977, 
Bochner et al., 1980).  
Fusaric acid is a Picolinic acid derivative and well-known metal chelating agent consisting of 
the chemical formula, C10H13O2N (ŠroBároVá et al., 2009). It contains the well conserved 
chelating structure of Picolinic acid and an additional fused aromatic ring structure or 5-butyl 
side chain (Figure 1.3) (Bochner et al., 1980). The butyl side chain is an important component 
in the structure of FA as it increases the lipophilicity of FA, enabling it to penetrate cell 
membranes which are mostly composed of lipids (Bochner et al., 1980). The structure of FA 
also contains a hydroxyl (OH
-
) group that acts as a proton donor and is responsible for most of 
the weak acid properties of FA. 
Fusaric acid is a pyridine derivative and chelator of divalent cations (Li et al., 2013). Like 
Picolinic acid, it is capable of forming conjugates with zinc, iron, copper and manganese 
thereby, forming chelates that make these ions inaccessible (Li et al., 2013). This occurs via the 
N-atom of the pyridine ring of FA which binds with the carboxyl group of the metal thereby, 






Figure 1.3: Structural comparison between nicotinic acid (A), Picolinic acid (B) and Fusaric 
acid (C) (May et al., 2000) 
1.2.2. Effects of Fusaric Acid 
 
Fusaric acid is a non-specific fungal toxin known to have numerous effects in both plants and 
animals (ŠroBároVá et al., 2009). However, the exact mechanism of action is yet to be 
elucidated. Fusaric acid is a well-known phytotoxin that causes wilt disease symptoms (necrotic 
spots on leaf blades, shrivelling and drying of leaves and shrinking of the stems and petioles) in 
a variety of plants (Rani et al., 2009, Pirayesh et al., 2015). Other effects of FA on plants 
include alterations in membrane permeability (Pavlovkin et al., 2004, D'Alton and Etherton, 
1984), increased electrolyte leakage (D'Alton and Etherton, 1984) and inhibition of respiration 




Fusaric acid is a cell membrane permeating weak acid and is therefore, potentially toxic as a 
proton conductor (Bochner et al., 1980). It alters the mitochondrial membrane potential of cells 
and decreases ATP production (Diniz and Oliveira, 2009, D'Alton and Etherton, 1984, 
Pavlovkin et al., 2004). This may occur by inhibiting cytochrome c oxidase and the 
ATPase/ATP synthase pump (Telles-Pupulin et al., 1996). Fusaric acid impairs mitochondrial 
function and biogenesis in HepG2 cells; and induces apoptosis by increasing the activity of 
caspases-3/7 (Abdul et al., 2016). Fusaric acid also elevates the oxidative stress biomarker lipid 
peroxidation and increases the activity of anti-oxidant enzymes: superoxide dismutase (SOD), 
catalase (CAT) and ascorbate peroxidase (Sapko et al., 2011). 
 
Fusaric acid is toxic to mice (intra peritoneal LD50 80mg/kg and intravenous LD50 100mg/kg) 
and death caused by the lethal dose has been attributed to its hypotensive effect (Hidaka et al., 
1969, Pirayesh et al., 2015). The ability of FA to cause a significant decrease in blood pressure 
has also been observed in cats, dogs, rabbits and rats as a result of the inhibition of dopamine-β-
hydroxylase (Pirayesh et al., 2015, Hidaka et al., 1969), a key enzyme in the synthesis of the 
neurotransmitter norepinephrine (Fairchild et al., 2005). Fusaric acid is a potent inhibitor of 
dopamine-β-hydroxylase and a decrease in the endogenous levels of norepinephrine has been 
observed in the heart, spleen, brain and adrenal glands of rats (Terasawa and Kameyama, 1971, 
Hidaka et al., 1969).   
The removal of essential metal ions by FA may serve as a mechanism by which this compound 
exerts its toxicity (Stack et al., 2004). Studies on several human cancers (mainly epidermoid 
cancers such as adenocarcinoma and hepatocellular carcinoma) revealed that FA has anti-
tumour activity (Rani et al., 2009, Stack Jr et al., 2014, Stack et al., 2004). Fusaric acid has anti-
tumour activity against head and neck squamous cell carcinoma (HNSCC) by increasing DNA 
damage and preventing its synthesis and repair (Stack et al., 2004, Stack Jr et al., 2014). This 
may occur due to the chelation of divalent cations from catalytic DNA associated 
metalloproteins (Stack et al., 2004) and inactivation of  zinc finger proteins (Rani et al., 2009).  
Two HNSCC cell lines (UMSCC-1 and Cal-27 cells) and a mouse model showed FA to have 
both tumouristatic and tumouricidal effects respectively (Stack et al., 2004). The removal of 
metal ions by FA inhibits metal-containing oxidative enzymes (Rani et al., 2009) and alters the 
conformation of proteins that require metal ions in order to maintain structural stability. Fusaric 
acid also increases cytokine production in Hep-2 (human cervical carcinoma cells) and Hep-
DOC (docetaxel-resistant Hep-2 cells) cells and this may be responsible for the cytostatic and 




fibroblasts and is a potent inhibitor of DNA synthesis in MDA-MB-468 cells and WI-38 
fibroblasts (Fernandez-Pol et al., 1993). 
Another study showed FA to be toxic to mice by chelating calcium causing a delay in bone 
ossification and affecting the growth of foetuses (Reddy et al., 1996). Fusaric acid was also 
shown to be toxic to zebrafish by chelating copper and inhibiting the enzyme lysyl oxidase 
resulting in notochord malformation (Yin et al., 2015). 
Fusaric acid is known to enhance the toxicity of other mycotoxins in both plants and animals 
(Bacon et al., 1996). Fusaric acid is not the only mycotoxin produced by the Fusarium species. 
Other mycotoxins such as zearalenones, trichothecenes and fumonisins are also produced by the 
Fusarium species (Bennett and Klich, 2003, Peraica et al., 1999). These mycotoxins are 
common contaminants of various food commodities and are often produced in combination with 
FA. Therefore, the toxicity of FA may be ascribed to its ability to act synergistically with other 
mycotoxins (Bacon et al., 1996). 
A study conducted on pigs indicated that FA increased the toxicity of deoxynivalenol (a β-
trichothecene) by competing with tryptophan for binding to blood albumin and therefore, 
increased the concentration of free tryptophan in the blood. This leads to an increased uptake of 
tryptophan in the brain and increased serotonin synthesis (Smith et al., 1997). 
Exposure to FA enhanced vomiting, feed refusal and brain metabolism in pigs given 
trichothecenes (Smith and MacDonald, 1991).  However, Ogunbo et al. (2007), showed no toxic 
synergy between FA and T2-toxin in broiler chicks and young turkey poults. This is in keeping 
with the findings of Fairchild et al. (2005) in which FA had no significant effect on body weight 
and body weight gains in turkey poults when fed up to 300 ppm of FA. Fusaric acid also dose-
dependently increased food intake in chicks (Bungo et al., 1999). 
Synergism between 4, 15-diacetoxyscirpenol (DAS) (a type A trichothecene) and FA has been 
demonstrated in insects (Dowd, 1988). Fusaric acid enhanced the toxicity of DAS in insects as it 
increased mortality from 5% with DAS alone to over 20% with DAS and FA combined (Dowd, 
1988). However, FA antagonized the negative effects caused by DAS alone (Dowd, 1988). 
Similar results were obtained by Fairchild et al. (2005) in which turkey poults fed a combination 
of DAS and FA showed a recovery in body weight and body weight gains as opposed to a diet 
with FA and DAS alone. 
Fumonisin B1 is another mycotoxin produced by the Fusarium species (Bennett and Klich, 




Fumonisin B1 on chicken embryos revealed that the treatment of chicken embryos with FA and 
Fumonisin B1 alone did not cause a toxic response. However, when combined a toxic response 
was observed (Bacon et al., 1995). This suggests that FA may have a synergistic effect with 
Fumonisin B1 (Bacon et al., 1995).  Although, no synergistic effects were observed with FA and 
Fumonisin B1 in rats (Voss et al., 1999). 
1.3. Apoptosis: Programmed Cell Death 
 
Apoptosis (programmed cell death) is responsible for the deletion of cells in normal tissues as 
well as in some pathological states (Kerr et al., 1994). It is a sequential process involving cell 
shrinkage, chromatin condensation, DNA fragmentation, membrane blebbing and the formation 
of apoptotic bodies. The apoptotic bodies are phagocytosed and digested by nearby resident 
cells (macrophages and other phagocytes), preventing the spillage of intracellular contents and 
avoiding inflammatory changes (Kerr et al., 1994). Apoptotic bodies not subjected to 
phagocytosis are released into the adjacent lumen where they display progressive dilation and 
degradation of cytoplasmic organelles in a process known as necrosis. Necrosis differs from 
apoptosis in which the cell swells and the plasma membrane ruptures releasing cytosolic 
contents into the extracellular space where they produce an inflammatory response (Woodle and 
Kulkarni, 1998).  
1.3.1. Caspases 
 
Caspases also known as death proteases are a group of cysteine proteases responsible for the 
initiation and execution of apoptosis (Hengartner, 2000). Caspases consist of an active-site 
cysteine and are known to cleave substrates after aspartic acid residues (Asp-Xxx) (Hengartner, 
2000). In order to control the apoptotic process, caspases are initially synthesized as inactive 
zymogens. These zymogens consist of three domains – an N-terminal pro-domain, a p20 
domain and a p10 domain. Proteolytic cleavage of these zymogens between the p20 and p10 
domains as well as between the pro-domain and p20 domain leads to the activation of caspases 
(Hengartner, 2000). Caspases act by inactivating or activating apoptotic-regulatory proteins and 





Initiator caspases such as caspase-2, -8 and -9 are the apical caspases in apoptosis and their 
activation is required for the cleavage and activation of the downstream executioner caspases-3, 
-6 and -7. The activation of executioner caspases usually ensures that apoptosis occurs 
(Hengartner, 2000, Hongmei, 2012). 
1.3.2.  Pathways of Apoptosis 
 
Apoptosis is triggered by a variety of physiological death signals as well as pathological cellular 
insults (Hongmei, 2012). It occurs via several pathways of which the two most common 
pathways involve caspase activation and are termed the intrinsic/mitochondrial pathway and the 
extrinsic/death receptor pathway. 
1.3.2.1. The Intrinsic/Mitochondrial Apoptotic Pathway 
 
The intrinsic apoptotic pathway is initiated in response to radiation, viral infection, irreparable 
DNA damage and oxidative stress (Hongmei, 2012). The mitochondria are central components 
of the intrinsic apoptotic pathway as it is the site where most of the pro- and anti-apoptotic 
molecules are located (Gross et al., 1999). Anti-apoptotic molecules such as BCL-2 are found 
on mitochondrial membranes whereas pro-apoptotic molecules such as BAX and cytochrome c 
are found in the cytosol and within the mitochondria respectively (Gross et al., 1999).  
 
BAX translocates from the cytosol to the mitochondria, following a death signal, where it 
undergoes a conformational change causing it to become an integral membrane protein (Gross 
et al., 1999). BAX interacts with members of the permeability transition pore (PTP; adenine 
nucleotide translocator (ANT), voltage-dependent anion channel (VDAC) and peripheral 
benzodiazepine receptor (PBR)) on the mitochondrial membrane resulting in the opening of the 
PTP and the release of cytochrome c and apoptosis inducing factor (AIF) from the mitochondria 
(Gross et al., 1999, Hongmei, 2012). The release of cytochrome c enables binding with the 
apoptotic protease activating factor-1 (Apaf-1), pro-caspase-9 and ATP to form an apoptosome. 
Apoptosome formation activates caspase-9, consequently activating executioner caspases-3/7 
resulting in apoptotic cell death (Figure 1.4) (Hengartner, 2000, Fulda, 2010). 
BCL-2 is an anti-apoptotic molecule that plays an important role in maintaining the integrity of 




release and the activation of caspases thus preventing apoptosis (Rego et al., 2001). Following 
apoptotic stimuli, the BH3-domain-only molecule (BIM) translocates to the mitochondria where 
it interacts with BCL-2 to antagonize its anti-apoptotic activity and promote apoptosis (Gross et 
al., 1999). 
1.3.2.2. The Extrinsic/Death Receptor Pathway 
 
The binding of death inducing ligands or soluble factors to death receptors on cell membranes 
leads to the activation of the extrinsic apoptotic pathway. In this pathway, death ligands such as 
tumour necrosis factor alpha (TNF-α), tumour necrosis factor related apoptosis inducing ligand 
(TRAIL) and Fas ligand (FasL) bind to their death receptors on the cells surface, type 1 TNF 
receptor (TNFR1), death receptor 4/5 (DR4/5) and Fas respectively (Okada and Mak, 2004, 
Hongmei, 2012). These death receptors have an intracellular death domain that recruits adaptor 
proteins such as TNF-receptor associated death domain (TRADD), Fas associated death domain 
(FADD) and cysteine proteases such as caspase-8. The binding of an adaptor protein to the 
death ligand-death receptor complex results in the formation of a death inducing signalling 
complex (DISC). DISC is responsible for the assembly and activation of pro-caspase-8 to 
caspase-8. Caspase-8 activates caspase-3/7 which leads to apoptosis (Figure 1.4) (Gross et al., 
1999, Hongmei, 2012, Fulda, 2010).  
The activation of the extrinsic apoptotic pathway can lead to the activation of the intrinsic 
apoptotic pathway via the BH3-domain-only molecule, Bid (Gross et al., 1999). The activation 
of caspase-8 (via the extrinsic apoptotic pathway) results in the cleavage of cytosolic p22 Bid at 
the amino terminus leading to the generation of a p15 carboxy-terminal fragment of Bid, 
truncated p15 Bid (tBid). tBid translocates to the mitochondria and directly activates pro-
apoptotic proteins to induce mitochondrial outer membrane permeabilization (Chipuk and 
Green, 2006). This leads to the release of cytochrome c and activation of the intrinsic apoptotic 





Figure 1.4: Extrinsic and Intrinsic Pathways of Apoptosis (Favaloro et al., 2012) 
1.4. DNA Damage  
 
Irreparable DNA damage is the major initiating event in apoptosis. DNA damage is caused by 
several endogenous (oxidative stress, replication errors) and exogenous (UV radiation, 
chemicals, toxins) agents. Common types of DNA damage include covalent modifications of 
bases (oxidation, hydrolysis, alkylation), breaks in the DNA backbone occurring in one (single-
strand) or both (double-strand) DNA strands and crosslinks between bases on the same or 
opposite DNA strands and between DNA and protein molecules (Figure 1.5) (Sancar et al., 
2004). Cells have evolved numerous mechanisms of halting cell division and repairing DNA 
damage (Sancar et al., 2004). However, sometimes DNA damage is so extensive it cannot be 
repaired and the affected cell is removed via apoptosis (Hongmei, 2012). In the event that 
apoptosis does not occur, normal functioning of the cell is disrupted and base lesions 





Figure 1.5: Common types of DNA damage (Prepared by author) 
1.5. The p53 Tumour Suppressor Protein 
 
DNA damage is the most common cause of p53 activation. p53 is a tumour suppressor protein 
and transcription factor involved in regulating the expression of genes critical for cell cycle 
arrest and apoptosis (Brooks and Gu, 2003, George, 2011, Reed and Quelle, 2014). It is encoded 
by one of the most frequently mutated genes in human cancers and more than 50% of cancers 
have been reported to contain mutated or inactive p53 (Barlev et al., 2001, George, 2011, 
O’Brate and Giannakakou, 2003, Zhang et al., 2015). 
p53 plays a major role in several cell signalling pathways and is activated in response to DNA 
damage, hypoxia, excessive oncogene activation and other stressors (Figure 1.6) (Prives and 
Hall, 1999). Once activated, p53 acts as a critical regulator of cell proliferation by functioning 
as a checkpoint protein to monitor DNA damage, arrest the cell cycle and initiate DNA repair 
prior to cell division (Barlev et al., 2001). p53 also mediates apoptosis in cells with irreparable 
DNA damage. In this way, p53 functions to maintain genomic stability and is often referred to 




p53 also activates the transcription of certain genes such as MDM2, p21 and BAX which are 
involved in regulating cell proliferation and apoptosis. It serves as a negative transcription factor  
to down-regulate the gene expression of BCL-2 (Kang et al., 2015) and can bind directly to anti-
apoptotic BCL-2 proteins and activate pro-apoptotic BCL-2 proteins (eg. BAX). This enables 
p53 to regulate mitochondrial outer membrane potential and apoptosis (Chipuk and Green, 
2006). 
 
Figure 1.6: Activation and function of p53 (Prepared by author) 
1.5.1. The Structure of p53 
 
The p53 gene, TP53, is located on the short arm of human chromosome 17 (17p13.1) and 
encodes a 53kDa nuclear phosphoprotein upon translation (George, 2011). The p53 protein 
consists of 393 amino acids and is made up of three main regions – an acidic N-terminal region, 
a central core region and a basic C-terminal region (Figure 1.7). The N-terminal region includes 
a transactivation domain and a proline rich domain. The transactivation domain consists of 
amino acids 1 to 42 and is involved in the activation of transcription factors (George, 2011, 
Lambert et al., 1998). It interacts with several proteins such as MDM2, TATA-binding protein 
(TBP) and protein kinases that regulate the stability and activity of p53 (Chao et al., 2003, 
Lambert et al., 1998, Thakur et al., 2012). The proline rich domain consists of amino acids 63 to 





The central core region comprises of a DNA-binding domain (amino acids 98 to 292) that 
interacts with DNA in a sequence-specific manner. The DNA binding domain consists of two 
copies of the 10bp consensus sequence, 5'-PuPuPuC(A/T)(A/T)GPyPyPy-3' (Pu=A/G, Py=T/C), 
separated by approximately 0 to 13bp (Benchimol, 2001) and it is the site where the majority of 
cancer associated mutations are detected (Prives and Hall, 1999). These mutations are usually 
missense mutations that alter the conformation of the DNA-binding domain and prevent the 
binding of p53 to DNA (Dai and Gu, 2010, Prives and Hall, 1999). This domain is stabilized by 
the tetrahedral coordination of a zinc ion with cysteine 176, histidine 179, cysteine 238 and 
cysteine 242 (Joerger and Fersht, 2010).  
 
The C-terminal region comprises of a tetramerization domain and a regulatory domain. The 
tetramerization domain (amino acids 324 to 355) is involved in the oligomerization and 
activation of p53. The regulatory domain (amino acids 363 to 393) functions as a transcriptional 
regulator and is involved in recognizing DNA damage. The C-terminal region also contains 
three nuclear localization signals (NLS) and two nuclear export signals (NES) that are 
responsible for the import and export of p53 to and from the nucleus (O’Brate and 
Giannakakou, 2003).  
 
 
Figure 1.7: Structure of p53 (Prepared by author) 
1.5.2. Post-translational Modifications of p53 
 
p53 is synthesised in the cytoplasm where it remains latent in the absence of cellular stress 
(George, 2011, O’Brate and Giannakakou, 2003). Exposure to stress such as DNA damage, 




exerts its transcriptional effects (O’Brate and Giannakakou, 2003). p53 can also function in a 
transcription-independent manner in the cytoplasm to regulate processes such as autophagy and 
apoptosis (Dai and Gu, 2010, Green and Kroemer, 2009).  
The tight regulation of p53 function is essential for maintaining normal cell growth and 
preventing tumourigenesis (Brooks and Gu, 2003). p53 is subjected to a variety of post-
translational modifications that regulate its function as a tumour suppressor protein (van 
Leeuwen et al., 2013). These modifications occur mainly in the N- and C-terminal regions of 
the protein and include ubiquitination, phosphorylation and acetylation (Barlev et al., 2001, 
Reed and Quelle, 2014, van Leeuwen et al., 2013). Other post-translational modifications of p53 
include neddylation, sumoylation and methylation (Dai and Gu, 2010). 
1.5.2.1. Ubiquitination of p53 
 
In normal healthy cells, p53 is a short-lived protein (half-life of approximately 10 min) that is 
maintained at very low levels due to the continuous ubiquitination by the protein MDM2 
(Thakur et al., 2012). MDM2 is synthesised in the cytoplasm and must translocate to the 
nucleus where it functions to ubiquitinate p53. The phosphorylation of MDM2 on Serine 166 
and 168 by phosphoinositol 3 kinase (PI3K) and protein kinase B (PKB) result in the 
translocation of MDM2 from the cytoplasm to the nucleus (O’Brate and Giannakakou, 2003).  
Ubiquitination refers to the covalent conjugation of one or more ubiquitin molecules to a protein 
substrate. This process plays a key role in regulating p53 stability and localization. MDM2 is a 
major E3 ubiquitin ligase and negative regulator of p53 (Dai and Gu, 2010, Brooks and Gu, 
2003). It ubiquitinates p53 at lysine (K) residues (K370, K372, K373, K381, K382 and K386) 
within the C-terminal regulatory domain (Dai and Gu, 2010). p53 can be mono-ubiquitinated or 
poly-ubiquitinated depending on the level of MDM2. High levels of MDM2 poly-ubiquitinates 
p53 whereas low levels of MDM2 mono-ubiquitinates p53 (Dai and Gu, 2010). 
The ubiquitination of p53 occurs in the nucleus and depending on the level of ubiquitination; 
p53 can undergo one of two fates. Poly-ubiquitinated p53 is generally degraded in the nucleus 
by the 26S proteasome whereas mono-ubiquitinated p53 inhibits DNA binding and is exported 
from the nucleus to the cytoplasm (Dai and Gu, 2010, Green and Kroemer, 2009, Reed and 
Quelle, 2014). In the cytoplasm, mono-ubiquitinated p53 can become further ubiquitinated by 
ARF-BP1 and Pirh2 and then degraded by the 26S proteasome (Dai and Gu, 2010, Green and 




mitochondria where it becomes de-ubiquitinated by the mitochondrial enzyme, Herpesvirus-
Associated Ubiquitin-Specific Protease (HAUSP). This leads to the generation of the 
apoptotically active non-ubiquitinated p53 which induces mitochondrial outer membrane 
permeabilization thus, triggering the release of pro-apoptotic factors and causing apoptosis in a 
transcription-independent manner (Figure 1.8) (Green and Kroemer, 2009). HAUSP is a direct 
antagonist of MDM2 activity and functions by specifically removing ubiquitin molecules from 
p53 when stimulated by DNA damage. Therefore, HAUSP protects p53 from MDM2-mediated 
degradation and allows the rapid accumulation of p53 upon DNA damage (Brooks and Gu, 
2003). 
MDM2 can also inhibit p53 transcriptional activity by binding directly to the N-terminal region 
of p53 and blocking the access of transcription factors to the transactivation domain of p53 
(George, 2011, Brooks and Gu, 2003). The MDM2 gene is an important transcriptional target of 
p53 and the stress-induced increase in p53 levels can induce the expression of MDM2, which in 
turn downregulates p53, creating a negative feedback loop (Dai and Gu, 2010, Gu et al., 2008). 
However, during apoptosis MDM2 is cleaved by caspase-3 generating a 60kDa fragment 
(molecular weight of MDM2 is normally 90kDa) that is capable of binding to p53 but lacks the 
characteristic E3 ubiquitin ligase activity (Pochampally et al., 1998). In this way, p53 is not 
targeted for degradation and hence it accumulates within cells. 
MDM2 has been established as an oncogene as its overexpression has been observed in several 
human cancers such as breast cancer, oesophageal cancer and ovarian cancer (Momand et al., 
1998). Overexpression of MDM2 conveys tumourigenic potential by diminishing the ability of 
p53 to induce cell cycle arrest and apoptosis in response to cellular stress (Pochampally et al., 
1998). The importance of MDM2 in regulating p53 activity was further determined by the 
observation that MDM2 null mice die as a result of p53-dependent apoptosis (Pochampally et 
al., 1998). 
1.5.2.2. Phosphorylation of p53 
 
p53 stabilization and transcriptional activation are crucial early events in a cell’s battle against 
genotoxic stress (Brooks and Gu, 2003). The p53 protein harbors an array of serine and 
threonine residues in the N-terminal transactivation domain and the C-terminal regulatory 
domain that are phosphorylated or dephosphorylated in response to genotoxic stress (Brooks 




Following DNA damage, p53 is imported from the cytoplasm to the nucleus where it becomes 
phosphorylated by several protein kinases such as ataxia telangiectasia mutated (ATM), ataxia 
telangiectasia and Rad 3 related (ATR), DNA-dependent protein kinase (DNA-PK), checkpoint 
kinases 1 and 2 (chk1 and chk2) and cyclin-dependent kinase activating kinase (CAK) (Figure 
1.8) (Barlev et al., 2001, Brooks and Gu, 2003, Dai and Gu, 2010, Reed and Quelle, 2014). 
These kinases are activated by various forms of DNA damage and directly phosphorylate p53 
on serine (Ser-15, Ser-20, Ser-33, Ser-37 and Ser-46) and threonine (Thr-18) residues (Reed and 
Quelle, 2014). Chk1 and chk2 can also phosphorylate C-terminal residues (Ser-313, Ser-314, 
Ser-315, Thr-377 and Ser-378) in response to DNA damage (George, 2011, Reed and Quelle, 
2014). The de-phosphorylation of p53 at Ser-15 and Ser-37 negatively regulates p53-dependent 
cell death and promotes cell survival (Li et al., 2006). Several studies show that DNA damage 
induced phosphorylation on Ser-15 and Ser-37 of p53 alleviates its inhibition by MDM2 and is 
essential for the stabilization of p53 during cellular stress (Shieh et al., 1997). However, others 
argue that the phosphorylation of p53 is necessary for its acetylation by increasing its 
interaction with transcriptional coactivators and histone acetyltransferases (Barlev et al., 2001, 
Kang et al., 2015, Lambert et al., 1998, Tang et al., 2008). 
1.5.2.3. Acetylation of p53 
 
The role of histone acetylation and its involvement in the regulation of transcription has long 
been a topic of interest. Histone acetylation, catalysed by histone acetyltransferases (HATs), 
refers to the covalent linkage of an acetyl group from acetyl coenzyme A to the epsilon (ε) 
amino group of lysine residues (Delcuve et al., 2012, Tang et al., 2008). Histone deacetylation is 
catalysed by histone deacetylases (HDACs) and involves the removal of acetyl groups from the 
lysine residues of histones (Delcuve et al., 2012). There are four classes of histone deacetylases 
– class I (HDACs 1, 2, 3 and 8), class II (HDACs 4, 5, 6, 7, 9 and 10), class III (Sirtuins 1-7) 
and class IV (HDAC 11). Histone acetylation and deacetylation modify chromatin structure and 
are known to affect many DNA based events such as replication and transcription (Delcuve et 
al., 2012).  
p53 was the first non-histone protein shown to be regulated by acetylation and deacetylation 
(Gu and Roeder, 1997). Several studies have shown that p53 acetylation is a crucial event that 
occurs in response to genotoxic stress and is essential for increasing p53 stability and 
stimulating its transcriptional activity (Barlev et al., 2001, Zhang et al., 2015, Solomon et al., 




DNA in a sequence-specific manner (Sakaguchi et al., 1998, Luo et al., 2004, Gu and Roeder, 
1997) and recruit transcriptional co-activators to specific p53 response elements (Barlev et al., 
2001).  
Histone acetyltransferases such as CREB-binding protein (CBP)/p300 and p300/CBP-associated 
factor (PCAF) mediates acetylation of the C-terminal lysine residues of p53 through interaction 
with its N-terminal region. Eight acetylation sites (K120, K320, K370, K372, K373, K381, 
K382 and K386) have been identified for p53, six of which were found to occur in the C-
terminal regulatory domain of p53 (K370, K372, K373, K381, K382 and K386) (Barlev et al., 
2001, Dai and Gu, 2010, Reed and Quelle, 2014). K382 is the major lysine residue acetylated in 
response to DNA damage and an increase in the acetylation of K382 has been shown to 
correlate with an increase in p53 phosphorylation (Reed and Quelle, 2014). K320 in the 
tetramerization domain of p53 is acetylated by PCAF, which favours cell survival by promoting 
p53 mediated activation of cell cycle arrest target genes (Dai and Gu, 2010). The acetylation of 
K120 in the DNA-binding domain of p53 was shown to be essential for p53-dependent 
apoptosis but has no effect on the induction of p21 and cell growth arrest (Tang et al., 2008). 
Recently it was observed that another lysine residue, K164, in the DNA-binding domain of p53 
is acetylated by CBP/p300 in response to DNA damage (Tang et al., 2008) and the acetylation 
of this lysine residue is involved in regulating a vast amount of p53 targets (Dai and Gu, 2010).  
Histone deacetylation plays a major role in inhibiting p53-dependent transcriptional activity, 
cell growth arrest and apoptosis (Reed and Quelle, 2014, Zhang et al., 2015). The major 
deacetylases involved in deacetylating p53 are HDAC1 and sirtuin (Sirt) 1 (Brooks and Gu, 
2003). HDAC1 is a zinc-dependent enzyme closely related to the yeast counterpart, RPD3 
(Delcuve et al., 2012). HDAC1 is found mainly in the nucleus and is responsible for 
deacetylating p53 at C-terminal lysine residues (K320, K373 and K382) thereby, inhibiting p53-
dependent transcription (Dai and Gu, 2010, Reed and Quelle, 2014, Zhang et al., 2015).  
Sirt1 is a class III NAD
+
-dependent deacetylase closely related to the yeast counterpart, Sir2 
(silent mating type information regulation 2). Sirt1 is predominantly localized in the nucleus 
where it catalyses the deacetylation of acetyl-lysine residues in a reaction that cleaves NAD
+
 
and generates O-acetyl ADP-ribose (Solomon et al., 2006). Sirt1 has been shown to deacetylate 
p53 specifically on K382, which is important for inducing cellular senescence in cells with 
minimal DNA damage (Wang et al., 2008). In addition, Sirt1 causes p53 hypo-acetylation and 
inhibits p53-mediated apoptosis. This is in accordance with a study by Cheng et al. (2003) in 




deacetylation of p53 by Sirt1 has also been shown to promote p53 nuclear export resulting in its 
accumulation within the cytoplasm. Increased cytoplasmic p53 may enhance its passage to the 
mitochondria where it induces apoptosis. Hence, Sirt1 may have a role in inducing apoptosis in 
a transcription-independent manner (Yi and Luo, 2010). Deacetylation of p53 by Sirt1 can also 
promote its ubiquitination and subsequent degradation (Barlev et al., 2001, Tang et al., 2008).  
Recently, it has been shown that p53 can be deacetylated in the cytoplasm and the deacetylase 
responsible for catalysing this reaction is the cytoplasmic Sirt2 (van Leeuwen et al., 2013). Sirt7 
was also found to interact with and deacetylate p53 in vitro (Vakhrusheva et al., 2008). This is 
in accordance with a study in which Sirt7-deficient cells were found to contain hyper-acetylated 
p53 (Vakhrusheva et al., 2008). 
1.5.3. The Role of MDM2 in Regulating p53 Acetylation  
 
The role of MDM2 in regulating the acetylation of p53 has received much interest over recent 
years. Some studies show that MDM2 can decrease the acetylation of p53 by ubiquitinating 
CBP/p300 and mediating its export from the nucleus to the cytoplasm, where it acts as an E4 
ubiquitin ligase to further ubiquitinate p53 and enable its degradation (Dai and Gu, 2010, Reed 
and Quelle, 2014, Zhang et al., 2015). Another study showed that p53 is ubiquitinated and 
acetylated on the same C-terminal lysine residues and hence, MDM2 and CBP/p300 may 
compete for the same binding sites (Brooks and Gu, 2003, Reed and Quelle, 2014, Zhang et al., 
2015). Acetylation of p53 inhibits MDM2-mediated ubiquitination by blocking the recruitment 
of MDM2 to p53 responsive promoters and vice versa (Zhang et al., 2015). MDM2 also 
promotes p53 deacetylation by recruiting HDAC1 to acetylated p53 complexes (Ito et al., 2002). 
The unmodified lysine residues then become substrates for MDM2-mediated ubiquitination 
resulting in p53 degradation (Ito et al., 2002). 























1.6. Problem Statement, Aims and Objectives 
 
Problem Statement 
Mycotoxin contamination of foods and feeds is a serious problem occurring worldwide 
(Milićević et al., 2010). South Africa is the major producer of maize and other cereal grains 
such as barley, wheat millets and sorghum. It is responsible for producing large quantities of 
agricultural crops each year. However, the lack of proper food storage methods accompanied 
with the hot and humid weather of SA provide ideal conditions for the growth of pathogenic 
fungi and the production of mycotoxins. Fusaric acid is an often neglected mycotoxin that 
contaminates a wide variety of food sources especially, maize which forms part of the staple 
diet. Several studies have reported FA to be a toxic agent in both plants (D'Alton and Etherton, 
1984, Diniz and Oliveira, 2009, Dong et al., 2012, Li et al., 2013, Sapko et al., 2011, Telles-
Pupulin et al., 1996) and animals (Terasawa and Kameyama, 1971, Smith and Sousadias, 1993, 
Ogunbo et al., 2007, Hidaka et al., 1969, Dowd, 1988, Bungo et al., 1999, Fairchild et al., 2005, 
Voss et al., 1999). However, the exact mechanism by which this mycotoxin exerts its toxicity is 
still unknown. p53 is a major stress response protein that regulates a variety of cellular 
processes and therefore, its activation may provide a possible mechanism by which FA induces 




To determine the effect of FA on DNA integrity and the post-translational modifications 
(phosphorylation and acetylation) of p53 in hepatocellular carcinoma (HepG2) cells. 
 
Null Hypothesis  




 To determine the effect of FA on DNA integrity in HepG2 cells at 24 hrs using the 





 To determine the effect of FA on the protein expression of p53, phosphorylated-Ser15- 
p53, acetylated-K382-p53, MDM2, acetylated-CBP (K1535)/p300 (K1499), HDAC1 
and phosphorylated-Ser47-Sirt1 in HepG2 cells at 24 hrs using western blot.  
 To determine the effect of FA on the cell cycle and apoptosis in HepG2 cells at 24 hrs 














Fusaric acid (FA), isolated from the fungus Gibberella fujikuroi (F6513), was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). The human hepatocellular carcinoma (HepG2) cell line 
was purchased from Highveld Biologicals (Johannesburg, SA). Cell culture equipment (cell 
culture flasks etc.) and reagents (Eagle’s Minimum Essentials Medium (EMEM), trypsin, trypan 
blue etc.) were purchased from Lonza Biotechnology (Basel, Switzerland). Western Blot 
equipment and reagents were purchased from Bio-Rad (Hercules, CA, USA). All other reagents 
were purchased from Merck (Darmstadt, Germany) unless otherwise stated. 
2.2. Cell Culture 
2.2.1. Introduction 
 
The HepG2 cell line, epithelial in morphology and consisting of 55 chromosome pairs, was 
derived from the liver tissue of a 15-year old Caucasian male possessing a well differentiated 
hepatocellular carcinoma. They are adherent cells that grow as monolayers or small aggregates 
in cell culture. Although often referred to as a liver cancer cell line, the HepG2 cells are a 
common and reliable model for liver toxicity testing. These cells contain many liver-specific 
genes, which produce plasma proteins, retain cell surface receptors, and can synthesise, 
assemble and secrete many low and high density lipoproteins similar to those of normal human 
hepatocytes (Dehn et al., 2004). HepG2 cells are also rich in Phase I (cytochrome P450 mono-
oxygenases) and Phase II (glucuronic and sulphate conjugation) biotransformation enzymes that 
play a vital role in normal biotransformation reactions and are essential for the detoxification of 





2.2.2. Cell Culture Conditions 
 
HepG2 cells were allowed to grow (37°C, 5% CO2) in 25cm
3
 sterile cell culture flasks 
containing complete culture media (CCM; Eagle’s Minimum Essentials Medium (EMEM) 
supplemented with 10% foetal calf serum, 1% penicillin-streptomycin-fungizone and 1% L-
glutamine). Cells were rinsed every two days in 0.1M phosphate buffered saline (PBS) and 
reconstituted with CCM (5ml). Once approximately 90% confluent, the cells were rinsed in 
0.1M PBS and incubated (37°C, 5% CO2) with the relevant treatment for 24 hrs. Thereafter, the 
cells were detached by incubation in 1ml trypsin (37°C, 5% CO2, 5 min) and used for the 
relevant assays. Cells were counted using the trypan blue cell exclusion method. 
2.3. Preparation of Fusaric Acid Treatment  
 
A 1mg/ml FA stock solution was prepared by dissolving 1mg of FA in 1ml 0.1M PBS. An 
inhibitory concentration of 50%  (IC50: 104µg/ml) was obtained from literature (Abdul et al., 
2016) (Appendix A) and used in all subsequent assays. Treatment of HepG2 cells were 
conducted over 24 hrs (37°C, 5% CO2) with 5ml of 104µg/ml FA (treatment). An untreated 
control (CCM only) was also prepared. 
2.4. Comet Assay 
2.4.1.  Introduction 
 
The comet assay also known as the single cell gel electrophoresis (SCGE) is a simple and rapid 
technique used to detect DNA strand breaks in individual cells (Collins, 2004, Fairbairn et al., 
1995, Tice et al., 2000). It was first introduced by Ostling and Johansen in 1984 and was later 
modified by Singh et al. (1988) to improve sensitivity.  
Cells are embedded in agarose gel on a microscope slide. The cells are lysed with detergents 
and high molarity sodium chloride to remove cellular proteins and the DNA is allowed to 
unwind in an alkaline medium. The cells are then electrophoresed at high pH resulting in 
structures that resemble comets, with a distinct head comprising of intact, undamaged DNA and 




(Collins, 2004, Tice et al., 2000). The length of the comet tail is directly proportional to the 
amount of DNA damage. 
The comet assay is based on the principle that the structure of DNA is a highly organised 
supercoil tightly packed with matrix proteins and chromatin in the nucleus. However, when 
DNA becomes damaged this highly organised structure is disrupted causing the individual DNA 
strands to relax. During electrophoresis, the applied electric field causes the negatively charged 
DNA (due to the phosphate backbone) to migrate towards the positively charged anode. 
Undamaged DNA is too large and does not migrate and hence do not produce comet-like 
images. However, the small fragments of damaged DNA migrates faster producing comet-like 
images when viewed using fluorescent microscopy (Collins, 2004, Fairbairn et al., 1995, Tice et 
al., 2000).  
2.4.2. Protocol 
 
The comet assay was used to determine the degree of DNA damage in HepG2 cells. Following 
incubation of HepG2 cells with FA for 24 hrs, the supernatants were removed, the cells were 
rinsed three times in 0.1M PBS and trypsinised. Thereafter, the cells were prepared in 0.1M 
PBS (20 000 cells in 25µl 0.1M PBS). 
Three frosted slides per sample (control and FA) were prepared by adding three layers of low 
melting point agarose gel (LMPA, 37°C) with each layer being allowed to solidify (4°C, 10 
min). The first layer consisted of 700µl 2% LMPA. The second layer consisted of 25µl cell 
suspension (20 000 cells in 0.1M PBS), 0.5µl Gel Red (catalogue no. 41003, Biotium Inc., 
Hayward, CA) and 175µl 1% LMPA and the third layer consisted of 200µl 1% LMPA. 
Thereafter, all slides were immersed in freshly prepared cold lysing solution [2.5M NaCl, 
100mM EDTA, 1% Triton X-100, 10mM Tris (pH 10) and 10% DMSO] and incubated (1 hr, 
4°C) to remove all cellular proteins. Following incubation, the slides were placed in 
electrophoresis buffer [300mM NaOH, 1mM Na2EDTA; pH 13] for 20 min at RT to allow DNA 
unwinding. The slides were then electrophoresed (25V (300mA), 35 min, RT) using the Bio-
Rad compact power supply. Following electrophoresis, the slides were washed three times with 
neutralisation buffer [0.4M Tris; pH 7.4] for 5 min each in order to remove excess detergents 
and alkali. Slides were viewed using the Olympus IX51 inverted fluorescent microscope with 
510-560nm excitation and 590nm emission filters (Figure 2.1). Images of at least 50 cells and 




using the Soft Imaging System (Life Science – Olympus Soft Imaging Solutions version 5) and 
reported as µm. 
 
Figure 2.1: Overview of the comet assay (Prepared by author) 
2.5. Hoechst 33342 Assay 
2.5.1.  Introduction 
 
Hoechst 33342 (2’-[4-ethoxyphenyl]-5-[4-methyl-1-piperazinyl]-2, 5’-bi-1H-benzimidazole 
trihydrochloride trihydrate) is a cell permeable fluorescent dye that binds specifically to the 
adenine-thymine (A-T) rich regions in the minor groove of DNA and emits an intense blue 




The Hoechst 33342 assay is a simple and rapid technique that allows easy visualization of the 
nucleus in interphase cells and chromosomes in mitotic cells (Chazotte, 2011). This allows one 
to observe cells at different phases of the cell cycle as well as those undergoing apoptosis.  
2.5.2. Protocol  
 
The Hoechst 33342 assay was used to determine the effect of FA on the cell cycle and apoptosis 
in HepG2 cells. HepG2 cells (500 000 cells/well) were seeded into a 6-well plate and allowed to 
adhere overnight. Thereafter, the CCM was removed; cells were rinsed three times using 0.1M 
PBS and treated with FA for 24 hrs. Three technical replicates were prepared. Following 
treatment, the cells were rinsed thrice in 0.1M PBS and fixed using 10% paraformaldehyde 
(500µl/well, 5 min, RT) to preserve the morphology and viability of the cells. Once fixed, the 
paraformaldehyde was removed and the cells were rinsed thrice in 0.1M PBS to remove excess 
paraformaldehyde. The Hoechst 33342 working solution (catalogue no. B2261, Sigma-Aldrich; 
500µl/well, 5µg/ml) was added and the plate was incubated (15 min, 37°C). Thereafter, the cells 
were rinsed thrice in 0.1M PBS to remove any unbound stain and viewed using the Olympus 
IX51 inverted fluorescent microscope with 350nm excitation and 450nm emission filters. Three 





Figure 2.2: Overview of the Hoechst 33342 Assay (Prepared by author) 
2.6. Western Blot 
 
Western Blot is an analytical technique that utilises the principle of antigen-antibody binding to 
detect and quantify specific proteins in a given sample (Eslami and Lujan, 2010, Mahmood and 
Yang, 2012). First, proteins are separated according to their molecular weights in a process 
known as sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). In SDS-
PAGE, a voltage is applied causing the negatively charged proteins to migrate towards the 
positively charged electrode through a gel matrix. This migration separates proteins according 
to their size with the higher molecular weight proteins migrating slower through the matrix and 
the lower molecular weight proteins migrating faster (Mahmood and Yang, 2012). Once 
electrophoresis is complete, the proteins are electro-transferred to a nitrocellulose membrane 
and incubated in blocking buffer to prevent the non-specific binding of proteins. The 
membranes are then immunoblotted with a specific primary and enzyme-conjugated secondary 




proteins to be detected and quantified from a sample containing several different proteins 
(Mahmood and Yang, 2012).  
2.6.1.  Protein Isolation 
2.6.1.1. Introduction 
 
Total protein was isolated from HepG2 cells using the Cytobuster™ Protein Extraction Reagent 
(catalogue no. 71009-4, Novagen, Bloemfontein, SA). Cytobuster is a gentle non-ionic reagent 
that consists of a variety of detergents that when combined with the mechanical scraping of cells 
disrupts cell membranes allowing for the efficient extraction of soluble proteins that are 
functionally active and expressed within cells. Loss of cell compartmentalization during protein 
isolation results in the release of several tightly regulated proteases and phosphatases that 
degrade and damage cellular proteins. In order to prevent the degrading properties of these 
enzymes, the lysis reagent is supplemented with protease and phosphatase inhibitors that 
inactivate endogenous proteolytic and phospholytic enzymes. This enables proteins to maintain 
their integrity and avoid becoming denatured.  
2.6.1.2. Protocol 
 
HepG2 cells were treated with FA for 24 hrs. The supernatants were removed from the flask and 
the cells were rinsed three times in 0.1M PBS. Thereafter, Cytobuster reagent (200µl) 
(Novagen, catalogue no. 71009) supplemented with a cocktail of protease inhibitors (Roche, 
catalogue no. 05892791001) and phosphatase inhibitors (Roche, catalogue no. 04906837001) 
was added to the flask and the cells were kept on ice for 30 min. The protein from the untreated 
and treated cells was further extracted using a cell scraper. The lysed cells were transferred to 
1.5ml micro-centrifuge tubes and centrifuged (10 000xg, 10 min, 4°C). The supernatants 
containing the crude protein extract was aspirated into fresh 1.5ml micro-centrifuge tubes and 





2.6.2. Quantification and Standardisation of Proteins 
2.6.2.1. Introduction 
 
The total crude protein was quantified using the Bicinchoninic Acid (BCA) Assay. The BCA 
assay was first invented by Paul K. Smith in 1985. It is a colorimetric assay based on the biuret 
reaction in which cupric (Cu
2+
) ions are converted to cuprous (Cu
+
) ions in an alkaline medium 
(Walker, 1996). First, the Cu
2+
 ions react with the peptide bonds in proteins and are reduced to 
form Cu
+
 ions. The Cu
+
 ions then react with two molecules of BCA to form a BCA-Cu
+
 
complex that has an intense purple colour and maximally absorbs light at a wavelength of 
562nm (Figure 2.3 and Figure 2.4). The intensity of the purple colour produced is directly 
proportional to the number of peptide bonds participating in the reaction and is an indication of 
the amount of protein present in the sample (Walker, 1996). 
 





2.6.2.2. Protocol  
 
Bovine serum albumin (BSA) standards [0, 0.2, 0.4, 0.6, 0.8 and 1mg/ml] were prepared in 
distilled water. Thereafter, 25µl of each standard (triplicate) and protein sample (duplicate) was 
pipetted into a 96-well microtiter plate. A working solution (200µl) consisting of 198µl BCA 
and 4µl CuSO4 was added to each well and the plate was incubated at 37°C for 30 min. The 
absorbance at 562nm was measured using a spectrophotometer (Bio-tek µQuant Plate Reader). 
The absorbances of the BSA standards were used to construct a standard curve from which the 
concentration of protein present in each sample was determined (Appendix B). 
The proteins were subsequently standardised to a concentration of 1.5mg/ml in Cytobuster 
reagent and the standardised samples were prepared in laemmli buffer [dH2O, 0.5M Tris-HCl 
(pH 6.8), glycerol, 10% SDS, 5% β-mercaptoethanol and 1% bromophenol blue] by boiling for 
5 min. Each component of the laemmli buffer has a specific function. Tris-HCl serves as the 
buffer and maintains pH. Glycerol adds weight to the samples allowing the samples to sink 
easily into the wells of the gel in SDS-PAGE (Mahmood and Yang, 2012). Bromophenol blue 
allows visualization of the samples as they migrate through the gel. SDS denatures proteins and 
imparts an overall negative charge enabling the proteins to be separated solely based on their 
size rather than charge and shape (Mahmood and Yang, 2012). The β-mercaptoethanol acts as a 
reducing agent to break disulphide bonds and denature the proteins. Following protein 





Figure 2.4: Overview of the isolation, quantification and standardisation of proteins (Prepared 
by author) 
2.6.3.  Preparation of Gels for SDS-PAGE  
2.6.3.1. Introduction 
 
Polyacrylamide gels are a 3D polymer network composed of acrylamide and a cross-linker 
known as N, N’-methylene bis-acrylamide under the catalyzation of ammonium persulfate 
(APS). SDS-PAGE utilises two types of agarose gels to separate proteins according to their 
molecular weights. The higher gel is known as the stacking gel and is slightly acidic (pH 6.8) 
with a low polyacrylamide content causing the gel to have large pores that poorly separate 
proteins (Mahmood and Yang, 2012). However, the stacking gel is important as it enables the 
protein to form thin sharply defined bands so that they can be separated by the lower resolving 




have narrower pores which function to separate proteins according to their size (Mahmood and 
Yang, 2012).  
2.6.3.2. Protocol 
 
Gels for SDS-PAGE were prepared using the Mini-PROTEAN Tetra Cell casting stand (Figure 
2.5) (Bio-Rad). A 10% resolving gel [dH2O, 1.5M Tris (pH 8.8), 10% SDS, bis-acrylamide, 
10% APS and TEMED] was prepared and allowed to polymerize for 1 hr. Thereafter, a 4% 
stacking gel [dH2O, 0.5M Tris (pH 6.8), 10% SDS, bis-acrylamide, 10% APS and TEMED] was 
prepared and added on top of the resolving gel. A 1cm plastic comb was placed between the 
glass plates to enable the formation of wells for sample loading (Figure 2.5 and Figure 2.6) and 
the gel was allowed to set for approximately 40 min.  
 
























2.6.4.  SDS-PAGE 
 
The gel cassettes were placed into the electrode assembly and the electrode tank (Mini-
PROTEAN Tetra Cell System, Bio-Rad). The protein samples (25µl) along with a molecular 
weight marker (5µl) (Precision Plus Protein All Blue Standards, catalogue no. #161-0373, Bio-
Rad) was loaded into the wells. The tank was filled with running buffer [25mM Tris, 192mM 
glycine and 0.1% SDS] and the samples were electrophoresed at 150V for 1 hr using the Bio-
Rad compact power supply (Figure 2.7). 
 







2.6.5.  Protein Transfer 
 
Once electrophoresis was complete, the separated proteins were transferred to a nitrocellulose 
membrane. The electrophoresed gels were gently removed from the glass plates and the stacking 
gel was removed. The electrophoresed gels, nitrocellulose membranes and two fibre pads were 
equilibrated in transfer buffer [25mM Tris, 192mM glycine and 20% methanol, pH 8.3] for 10 
min. Thereafter, a gel sandwich consisting of a fibre pad, nitrocellulose membrane, gel and fibre 
pad (Figure 2.8) was assembled between the two electrodes in the transfer apparatus and the 
separated proteins were electro-transferred to the nitrocellulose membrane using the Bio-Rad 
Trans-Blot Turbo Transfer System (30 min, 20V). 
The application of the voltage generates an electric current perpendicular to the surface of the 
gel. This causes the negatively charged proteins to migrate out of the gel and onto the 
nitrocellulose membrane.  
 





2.6.6.  Blocking and Antibody Incubation 
 
After transfer, the membranes were blocked in 5ml blocking buffer consisting of either 5% BSA 
or 5% non-fat dry milk (NFDM) in Tris buffered saline with 0.05% Tween 20 [TTBS; 150mM 
NaCl, 3mM KCl, 25mM Tris, 0.05% Tween 20, dH2O, pH 7.5] for 1 hr at RT with gentle 
shaking to prevent the non-specific binding of proteins. The membranes were then 
immunoblotted with the specific primary antibody (Table 1) for 1 hr on the shaker at RT and 
then overnight at 4°C. The primary antibody is specific to the target protein and hence will bind 
only to the target protein. Following the overnight incubation, the membranes were equilibrated 
to RT and washed five times with TTBS (10 min each, RT) to remove unbound primary 
antibody. The membranes were then incubated with the respective horse-radish peroxidase 
(HRP)-conjugated secondary antibody [1:10 000 dilution in 5% BSA (goat anti-rabbit, sc-2004) 
and 1:10 000 dilution in 5% NFDM (goat anti-mouse, sc-2005)] for 2 hrs at RT with gentle 
shaking. The secondary antibody is specific to the primary antibody and hence will bind only to 
the bound primary antibody. Following incubation, the membranes were washed five times with 















Table 1: Antibody Dilutions 
 
ANTIBODY DILUTION CATALOGUE NUMBER 
Anti-MDM2 1:1 000 in 5% NFDM M4308 (Sigma-Aldrich), 
mouse monoclonal 
Anti-p53 1:1 000 in 5% BSA Sc-6243 (Santa Cruz), rabbit 
polyclonal 
Anti-a-K382-p53 1:500 in 5% BSA #2525 (Cell Signalling 
Technology), rabbit 
polyclonal 
Anti-p-Ser15-p53 1:1 000 in 5% BSA #9284 (Cell Signalling 
Technology), rabbit 
polyclonal 




1:1 000 in 5% BSA #4771S (Cell Signalling 
Technology), rabbit 
polyclonal 
















The Clarity™ Western ECL Substrate Kit (catalogue no. #170-5060, Bio-Rad) consisting of a 
hydrogen peroxide substrate and an enhanced luminol solution was used for the antigen-
antibody complex and the signal was detected using the ChemiDoc™ XRS+ Molecular Imaging 
System (Bio-Rad). The HRP conjugated to the secondary antibody reacts with the hydrogen 
peroxide (H2O2) substrate to yield oxygen radicals. The oxygen radical reacts with luminol 
causing the luminol to break down into aminophtalic acid which in turn reacts with enhancer 
molecules causing it to luminesce enabling the visualization of protein bands (Figure 2.9). 
 
Figure 2.9: Principle of antigen-antibody binding and detection of proteins using the Clarity™ 








2.6.8.  Quenching and Normalisation 
 
After detection, the membranes were quenched using 5ml H2O2 (30 min, 37°C), washed once 
with TTBS (10 min, RT), blocked in 5% BSA in TTBS (1 hr, RT) and probed with the 
housekeeping protein, anti-β-actin (catalogue no. A3854, Sigma-Aldrich, 1:5 000 dilution in 5% 
BSA, 30 min, RT) in order to normalise protein expression and correct for loading error.  
Protein expression was analysed using the Image Lab Software version 5.0 (Bio-Rad) and the 
results were expressed as relative band density (RBD) and fold-change. Protein expression was 
normalised by dividing the RBD of the protein of interest by the RBD of β-actin. The 
normalised protein expression of the treatment was then divided by the normalised protein 
expression of the control to determine a fold-change relative to the control.  
2.7. Statistical Analyses  
 
Microsoft Excel 2010 and GraphPad Prism version 5.0 (GraphPad Software Inc., California) 
was used to perform all statistical analyses. The unpaired t-test with Welch’s Correction was 
used for all assays. All results were represented as the mean ± standard deviation unless 








3.1. Comet Assay 
 
The comet assay was used to assess DNA integrity in the FA treated and untreated control 
HepG2 cells at 24 hrs (Figure 3.1 A). The length of the comet tails were measured (µm) and are 
an indication of the amount of damaged DNA present within the cell (Figure 3.1 B). 
 
Figure 3.1: Comet tails of the FA treated and control HepG2 cells (20x magnification) (A) 





Fusaric acid induced DNA damage in HepG2 cells at 24 hrs. This is shown by the significant 
increase in comet tail lengths in the FA treatment [89.98 ± 10.36µm vs. 33.99 ± 6.76µm, 
p<0.0001] compared to the control (Figure 3.1). 
3.2. Western Blot  
 
Western blot was used to determine the effect of FA on the post-translational modifications, 
phosphorylation and acetylation, of p53. The protein expression of p53, phosphorylated-Serine 
15-p53 (p-Ser15-p53), acetylated-Lysine 382-p53 (a-K382-p53), acetylated-CBP (Lysine 
1535)/p300 (Lysine 1499) (a-CBP (K1535)/p300 (K1499)), HDAC1, phosphorylated-Serine 47-
Sirt1 (p-Ser47-Sirt1) and MDM2 in the FA treated and control HepG2 cells at 24 hrs was 
assessed. The expression of the target proteins was normalised against the housekeeping 
protein, β-actin. Results are expressed as fold-change relative to the control (control = 1-fold).    
3.2.1. p53  
 
The tumour suppressor protein, p53 is activated in response to DNA damage. Fusaric acid 
significantly decreased the protein expression of p53 in HepG2 cells (0.73 ± 0.03-fold vs. 1.02 ± 





Figure 3.2: Western blot images (A) and relative fold-change (B) of p53 expression in the FA 
treated and control HepG2 cells at 24 hrs (**p<0.005). 
3.2.2. Phosphorylated-Ser15-p53 and acetylated-K382-p53 
 
The phosphorylation and acetylation of p53 are the most common post-translational 
modifications that occur during DNA damage. Fusaric acid significantly increased the 
phosphorylation of p53 on the Ser-15 residue in HepG2 cells (9.76 ± 0.20-fold vs. 1.02 ± 0.01-
fold, p=0.0002) compared to the control (Figure 3.3). Acetylated p53 on the K382 residue was 
significantly increased in the FA treatment compared to the control (1.75 ± 0.23-fold vs. 1.02 ± 
0.01-fold, p=0.0329; Figure 3.4). These results indicate that FA not only alters the protein 





Figure 3.3: Western blot images (A) and relative fold-change (B) of p-Ser15-p53 expression in 
the FA treated and control HepG2 cells at 24 hrs (***p<0.0005). 
 
 
Figure 3.4: Western blot images (A) and relative fold-change (B) of a-K382-p53 expression in 





3.2.3. Acetylated-CBP (K1535)/p300 (K1499) 
 
CREB-binding protein and p300 regulate the acetylation of p53 on the K382 residue. Fusaric 
acid significantly decreased the expression of a-CBP (K1535)/p300 (K1499) in HepG2 cells 
compared to the control (0.58 ± 0.05-fold vs. 1.02 ± 0.01-fold, p=0.0043; Figure 3.5). 
 
Figure 3.5: Western blot images (A) and relative fold-change (B) of a-CBP (K1535)/p300 
(K1499) expression in the FA treated and control HepG2 cells at 24 hrs (**p<0.005). 
3.2.4. HDAC1 and p-Ser47-Sirt1 
 
The deacetylases, HDAC1 and Sirt1, are known to deacetylate p53 on K382.  The expression of 
HDAC1 was significantly reduced in the FA treated HepG2 cells compared to the control (0.84 
± 0.02-fold vs. 1.02 ± 0.01-fold, p=0.0006; Figure 3.6). However, the protein expression of p-
Ser47-Sirt1 was higher in the FA treatment compared to the control (1.24 ± 0.04-fold vs. 1.02 ± 





Figure 3.6: Western blot images (A) and relative fold-change (B) of HDAC1 expression in the 
FA treated and control HepG2 cells at 24 hrs (**p<0.005). 
 
 
Figure 3.7: Western Blot images (A) and relative fold-change (B) of p-Ser47-Sirt1 expression 






3.2.5. Murine Double Minute 2 (MDM2) 
 
The E3 ubiquitin ligase, MDM2, negatively regulates p53 expression by adding ubiquitin 
molecules to the C-terminal lysine residues of p53 targeting it for degradation by the 26S 
proteasome. The ubiquitination of p53, mediated by MDM2, is an important post-translational 
modification that occurs in the absence of cellular stress. The expression of MDM2 was 
significantly elevated in the FA treated HepG2 cells compared to the control (5.63 ± 0.78-fold 
vs. 1.02 ± 0.01-fold, p=0.0094; Figure 3.8). 
 
Figure 3.8: Western blot images (A) and relative fold-change (B) of MDM2 expression in FA 









3.3.  Hoechst 33342 Assay 
 
The Hoechst 33342 stain is a cell permeable fluorescent stain that binds specifically to the A-T 
rich regions of DNA enabling visualization of the different stages of cell division as well as 
gradations of nuclear damage. The Hoechst 33342 assay was used to determine the effect of FA 
on cell proliferation, cell cycle arrest and apoptosis in HepG2 cells at 24 hrs (Figure 3.9). 
Hoechst analysis of FA treated HepG2 cells at 24 hrs (Figure 3.9 B) displayed fewer cells with 
the absence of dividing cells and the presence of several apoptotic bodies compared to the 
control cells (Figure 3.9 A). Therefore, FA inhibited cell proliferation, caused cell cycle arrest 
and induced apoptosis in HepG2 cells. 
 
Figure 3.9: Hoechst 33342 staining of the control (A) and FA treated (B) HepG2 cells at 24 hrs 
(20x magnification). 
  
A.       Control                    B.            FA 

















Fusaric acid is a common mycotoxin produced by the Fusarium species and a natural 
contaminant of several food commodities, especially maize (Bacon et al., 1996). These foods 
form an integral part of local diets and the consumption of FA contaminated foods may be 
harmful to humans and animals.  
Fusaric acid is toxic to plants (D'Alton and Etherton, 1984, Diniz and Oliveira, 2009, Pavlovkin 
et al., 2004, Pirayesh et al., 2015, Rani et al., 2009) and animals (Bacon et al., 1995, Bungo et 
al., 1999, Dowd, 1988, Fairchild et al., 2005, Hidaka et al., 1969, Pirayesh et al., 2015, Rani et 
al., 2009, Terasawa and Kameyama, 1971, Voss et al., 1999). However, the mechanism by 
which this mycotoxin exerts its toxicity is currently unknown. Numerous studies have shown 
FA to exert its toxicity by elevating oxidative stress (Abdul et al., 2016, D'Alton and Etherton, 
1984, Diniz and Oliveira, 2009, Sapko et al., 2011). However, others show that FA is a potent 
chelator of divalent cations and thus may exert its toxicity by removing essential metal ions 
(Fernandez-Pol et al., 1993, Rani et al., 2009, Stack et al., 2004). 
This study aimed to determine a possible mechanism of FA induced toxicity in HepG2 cells at 
24 hrs. The ability of FA to cause DNA damage, post-translationally modify the tumour 
suppressor protein, p53, and induce cell death was determined.  
Due to its continuous replication, DNA is highly susceptible to damage by both endogenous and 
exogenous agents (Sancar et al., 2004). Damage to cellular DNA disrupts normal functioning of 
the cell and can lead to death of the cell or malignant transformation. The longer comet tail 
lengths observed in the FA treated cells compared to the control (Figure 3.1 A) indicate that FA 
increased DNA damage in HepG2 cells (Figure 3.1 B). The increase in DNA damage may be a 
result of an increase in oxidative stress as studies show that FA elevates oxidative stress (Abdul 
et al., 2016, Sapko et al., 2011). Oxidative stress refers to an increase in reactive oxygen species 
and a decrease in antioxidants (Södergren, 2000). Reactive oxygen species are highly reactive 
molecules that contain oxygen including superoxide radical (O2
.
), hydroxyl radical (HO
.
) and 
hydrogen peroxide (H2O2); that are capable of causing damage to cellular macromolecules 
(Södergren, 2000). Reactive oxygen species damage cellular DNA by oxidising DNA bases, 
causing breaks in the DNA molecule (single- and double-strand breaks) and by forming highly 




p53 is a major stress response protein that is activated in response to DNA damage (Brooks and 
Gu, 2003). Extensive DNA damage increases the steady-state level and activity of p53 leading 
to cell cycle arrest, inhibition of cell proliferation and apoptosis (Blattner, 2008). Fusaric acid 
significantly decreased the protein expression of p53 in HepG2 cells (Figures 3.2). p53 is a 
metalloprotein that requires a zinc atom in order to maintain structural stability. The zinc ion is 
coordinated by a histidine (His179) and three cysteine side chains (Cys176, Cys238 and 
Cys242) (Joerger and Fersht, 2007) and is essential for maintaining the wild-type conformation 
and stability of the p53 protein (Ostrakhovitch et al., 2006). The removal of the zinc ion by a 
metal chelating agent such as FA substantially destabilizes the p53 protein resulting in local 
structural perturbations and loss of sequence-specific DNA binding (Joerger and Fersht, 2007).  
p53 is subjected to a variety of post-translational modifications that enhance its stability and 
activity as a transcription factor (Brooks and Gu, 2003). During DNA damage, the kinases 
ATM, ATR and DNA-PK are activated to phosphorylate p53 on Ser-15 (Barlev et al., 2001, 
Blattner, 2008, Brooks and Gu, 2003, Dai and Gu, 2010, Reed and Quelle, 2014). Fusaric acid 
significantly increased the expression of p-Ser15-p53 in HepG2 cells (Figure 3.3). 
The phosphorylation of p53 on Ser-15 primes p53 for acetylation. This occurs by increasing the 
interaction between p53 and histone acetyltransferases and decreasing the interaction with 
MDM2 (Barlev et al., 2001, Kang et al., 2015, Lambert et al., 1998, Tang et al., 2008, Zhang et 
al., 2015). The histone acetyltransferases, CBP and p300 acetylate p53 on K382 (Barlev et al., 
2001, Dai and Gu, 2010, Das et al., 2014, Zhang et al., 2015). Fusaric acid significantly 
increased the expression of a-K382-p53 in HepG2 cells (Figure 3.4) despite the significant 
decrease in the expression of a-CBP (K1535)/p300 (K1499) (Figure 3.5). The acetylation of 
CBP on K1535 and p300 on K1499 is known to enhance the histone acetyltransferase activity of 
CBP and p300 (Das et al., 2014, Thompson et al., 2004).  These transcriptional co-activators 
function by directly binding to a variety of transcriptional regulators where they recruit 
additional CBP/p300 molecules to acetylate histones and non-histone proteins thereby, 
activating their transcriptional activity (Nyborg and Peersen, 2004). The structure of CBP/p300 
plays a major role in its HAT function (Das et al., 2014, Park et al., 2013). CBP/p300 contain 
several well conserved domains, three of which bind zinc and are required for the formation of a 
stable folded structure (Park et al., 2013, Nyborg and Peersen, 2004). The decrease in the 
expression of a-CBP/p300 observed in the FA treatment may be attributed to the removal of the 
zinc ions from the CBP/p300 protein leading to structural destabilization. Similar results were 
obtained by Nyborg et al. (2004) in which the zinc-chelating agent, EDTA, caused unfolding 




of acetyl-CoA (Black et al., 2008) and a decrease in CBP/p300 will ultimately lead to a decrease 
in a-CBP (K1535)/p300 (K1499).  
The decrease in a-CBP (K1535)/p300 (K1499) did not affect the acetylation of p53 as the 
phosphorylation of p53 on Ser-15 enables a-CBP/p300 to bind to p53 with a high affinity 
leading to C-terminal acetylation and enhanced transcriptional activity of p53 (Blattner, 2008).  
The acetylation of p53 promotes p53 mediated gene activation which ultimately determines the 
cells response to stress in the form of senescence, cell growth arrest and apoptosis (Barlev et al., 
2001, Blattner, 2008). Hoechst analysis of HepG2 cells showed that FA inhibited cell growth 
and possibly induced apoptosis, as shown by the absence of dividing cells and the presence of 
apoptotic bodies (Figure 3.9). This is in accordance with the study by Abdul et al. (2016) in 
which FA induced apoptosis in HepG2 cells by elevating the activity of the executioner 
caspases-3/7. Another study conducted by Ogata et al. (2001) showed that FA also effectively 
induced apoptosis in HL-60 (human promyelocytic leukaemia cells) cells.  
The deacetylases, Sirt1 and HDAC1 deacetylate and inactivate p53 (Brooks and Gu, 2003). 
HDAC1 is known to deacetylate p53 on several lysine residues (K320, K373 and K382). 
Fusaric acid significantly decreased the protein expression of HDAC1 and increased the 
expression of p-Ser47-Sirt1 in HepG2 cells (Figure 3.6 and 3.7 respectively). Sirt1 is an NAD+-
dependent deacetylase that is responsible for deacetylating p53 specifically on K382 (Wang et 
al., 2008). Sirt1 catalyses the deacetylation of lysine residues in a unique reaction that utilises 
NAD+ and generates nicotinamide and O-acetyl ADP-ribose (Avalos et al., 2005). 
Nicotinamide is a non-competitive inhibitor of Sirt1 activity (Avalos et al., 2005) and the 
inhibition of Sirt1 activity has been reported to suppress cell growth as well as induce cell cycle 
arrest and apoptosis in vitro (Wang et al., 2013). The function of Sirt1 is regulated by 
phosphorylation. Several protein kinases have been shown to phosphorylate Sirt1; however, 
whether or not Sirt1 is activated by phosphorylation is largely dependent on the protein kinase 
that phosphorylates it (Sasaki et al., 2008). For example, the phosphorylation of Sirt1 on Ser-47 
by JNK1 (c-Jun kinase) promotes its nuclear localization and enzymatic activity (Conrad et al., 
2016, Nasrin et al., 2009) whereas the phosphorylation of Sirt1 on Ser-47 by mTOR 
(mammalian target of rapamycin) was found to inhibit Sirt1 deacetylase activity (Back et al., 
2011).  
Sirt1 also contains a multifunctional domain known as the C-pocket that is capable of directly 
binding NAD+ and is involved in mediating NAD+ cleavage, base-exchange activity and 




reactions with the nicotinamide moiety of NAD+ thereby, forming NAD+ analogues (Bochner 
et al., 1980, Fernandez-Pol et al., 1977). Fusaric acid is a pyridine derivative and nicotinic acid 
related compound that may bind to the C-pocket of Sirt1 and inhibit its activity by preventing 
NAD+ from binding to the C-pocket and catalysing the deacetylation reaction. Fusaric acid may 
also mimic the structure of nicotinamide, bind to the C-pocket of Sirt1 and inhibit Sirt1 activity. 
Therefore, although FA elevated the expression of p-Ser47-Sirt1, it may not necessarily be 
active as an increase in a-K382-p53 was also observed. 
MDM2 plays the most central role in the regulation of p53. MDM2 binds and ubiquitinates p53 
targeting it for degradation by the 26S proteasome (Brooks and Gu, 2003). This enables p53 to 
be maintained at low levels in the absence of cellular stress. However, excessive p53 activation 
can increase the expression of MDM2 in a negative feedback loop to decrease p53 expression 
and activation (Brooks and Gu, 2003). Fusaric acid significantly increased the expression of 
MDM2 in HepG2 cells (Figure 3.8). The acetylation of p53 on K382 indicates an increase in p53 
stability and activity (Barlev et al., 2001, Brooks and Gu, 2003, Shieh et al., 1997, Sakaguchi et 
al., 1998). Therefore, the increase in MDM2 expression may occur in response to the increase in 
a-K382-p53 (increase in p53 activity) observed in the FA treated HepG2 cells. The decrease in 
p53 protein levels may not be attributed to the increase in MDM2 expression as the 
phosphorylation of p53 on Ser-15 prevents the interaction between p53 and MDM2 thereby, 
inhibiting its ubiquitination and degradation in the presence of DNA damage (Brooks and Gu, 
2003, Shieh et al., 1997).  
In response to DNA damage, ATM and DNA-PK are capable of phosphorylating both p53 and 
MDM2 (Shi and Gu, 2012). DNA-PK and ATM phosphorylate MDM2 on Ser-17 and Ser-395 
respectively. The phosphorylation of MDM2 on Ser-17 prevents MDM2 from binding and 
ubiquitinating p53 (Mayo et al., 1997) whereas the phosphorylation of MDM2 on Ser-395 
inhibits the export of p53 from the nucleus to the cytoplasm (Maya et al., 2001). This prevents 
p53 degradation and may provide a possible explanation for how p53 trans-activates the MDM2 
gene but is not initially inhibited by the resulting increase in MDM2 protein (Mayo et al., 1997, 
Maya et al., 2001). 
A summary of the effect of FA on DNA integrity and the post-translational modifications of p53 





Figure 4.1: Mechanism of FA induced toxicity in the HepG2 cell line. FA induces DNA 
damage in HepG2 cells. The protein kinases ATM, ATR and DNA-PK are activated in response 
to DNA damage. These protein kinases phosphorylate p53 on Ser-15. The phosphorylation of 
p53 alleviates the interaction between p53 and MDM2 and increases the interaction between 
p53 and a-CBP/p300. This leads to the acetylation of p53. The acetylation of p53 stabilises and 







The contamination of foods and feeds with mycotoxins is a serious problem that results in major 
economic losses and a huge impact on human and animal health (Milićević et al., 2010, Bennett 
and Klich, 2003, Zain, 2011, Yiannikouris and Jouany, 2002). The application of modern 
agricultural practices and the presence of legislatively regulated food processing help curb the 
extent of mycotoxin contamination; however, it does not totally eradicate it. Of major concern is 
the often neglected Fusarium produced mycotoxin, FA. It is well established that FA is a 
common contaminant of several food commodities and several studies have shown FA to be 
toxic (Abdul et al., 2016, Bacon et al., 1995, Bungo et al., 1999, Dowd, 1988, Fairchild et al., 
2005, Ogunbo et al., 2007, Pavlovkin et al., 2004, Smith and MacDonald, 1991, Smith et al., 
1997, Terasawa and Kameyama, 1971, Voss et al., 1999). However, limited scientific data is 
available on the mechanism by which FA exerts its toxic effects.  
Studies evaluating the mechanism of FA induced toxicity are important in understanding the 
risks of FA contamination to human and animal health. This is particularly relevant in 
developing countries and poverty stricken areas where exposure to mycotoxins is high due to 
the continuous consumption of contaminated agricultural commodities. 
This study, for the first time, provides a possible mechanism of FA induced toxicity in the 
human liver using the HepG2 cell line. The activation of p53 occurs in response to various 
cellular stressors such as DNA damage and may provide the most likely mechanism of FA 
induced toxicity. The results indicate that FA is genotoxic and post-translationally modified 
(increased the phosphorylation and acetylation) p53 leading to cell growth arrest and apoptosis 
of HepG2 cells. These findings correspond with the hypothesis which stated that FA induced 
DNA damage and post-translationally modified p53 in HepG2 cells. Interestingly, the results 
also indicate a control for p53 acetylation and highlight the importance of the regulation 
between p53 and MDM2 for cell development, proper protection from DNA damage, cell cycle 
control and growth. Furthermore, the results indicate that Ser-15 phosphorylation is required for 
p53 function and this may suggest a possible universal role in promoting p53-transcriptional 
activity and determining cell fate. Nevertheless, future studies are required to validate the 
mechanism of FA induced toxicity using an in vivo model. It would also be interesting to 
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Methyl Thiazol Tetrazolium (MTT) Assay 
 
The MTT assay is a colorimetric assay used to measure cell viability by determining 
mitochondrial activity. Mitochondrial activity is a common indicator of cell viability and is 
significantly reduced in dead and dying cells. The principle of the MTT assay is based on the 
reaction in which live metabolically active cells reduce the yellow tetrazolium salt (MTT; 3-[4, 
5-dimethylthiazol-2-yl]-2, 5-diphenyl-tetrazolium bromide) to a purple insoluble formazan 
product ((E, Z)-5-(4, 5-dimethylthiazol-2-yl)-1, 3-dimethylformazan) with the action of 
dehydrogenase enzymes. These enzymes utilise reducing equivalents such as NADH and 
FADH2 produced in the citric acid cycle to cleave the tetrazolium ring of MTT and produce the 
formazan product which can be solubilised and quantified using spectrophotometry (Mosmann, 
1983). The intensity of the formazan produced is proportional to the number of viable cells.  
Fusaric acid dose-dependently decreased the viability of HepG2 cells at 24 hrs (Figure 5). This 
indicates that FA is cytotoxic to HepG2 cells. The concentration of FA causing death of 50% of 
HepG2 cells (IC50) was determined to be 104µg/ml. This concentration was used as the 
treatment concentration for all subsequent assays. 
 
Figure 5: IC50 graph displaying the dose-dependent decline in HepG2 cell viability (%) at 24 hrs 






Bicinchoninic Acid (BCA) Assay 
 
 
Figure 6: Standard curve displaying known concentrations of bovine serum albumin (BSA) 
used to determine the concentration of protein present in each sample 
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Expression of p-ser15-p53 and a-K382-p53 relative to the total p53 expressed 
 
The expression of p-Ser15-p53 and a-K382-p53 were divided by the expression of total p53 in 
order to determine the ratio of p53 acetylated and phosphorylated relative to the total p53 
expressed within the cell. 
p-Ser15-p53/p53 
 
The ratio of p-Ser15-p53 to total p53 was significantly higher in the FA treated HepG2 cells 
compared to the control [13.42±0.32-fold vs. 1.02±0.01-fold, p=0.0002; Figure 7.1]. 
 









The ratio of a-K382-p53 to total p53 was significantly higher in the FA treated HepG2 cells 
compared to the control [2.41±0.33-fold vs. 1.02±0.01-fold, p=0.0181; Figure 7.2]. 
 









Table 3: Raw data/tail lengths (µm) obtained from the comet assay  
 
Control  Fusaric Acid Treatment 
45.59 76.11 
44.86 76.88 
43.87 77.12 
43.88 77.34 
43.78 77.40 
42.57 77.66 
42.57 78.65 
41.28 78.69 
42.50 78.69 
41.28 78.76 
38.62 79.87 
39.99 79.98 
39.99 81.27 
40.78 81.27 
38.70 81.56 
38.70 81.69 
37.41 82.09 
34.54 82.56 
37.41 83.67 
35.12 83.85 
36.19 84.78 
34.43 85.14 
37.12 85.14 
35.83 87.72 
34.83 89.01 
33.54 90.30 
32.25 90.97 
34.34 91.59 
32.25 91.78 
33.56 92.88 
32.25 94.17 
30.96 95.46 
32.24 95.46 
29.67 96.74 
 
79 
 
29.67 96.75 
28.35 98.04 
28.45 98.05 
27.12 98.19 
28.09 98.24 
27.08 98.46 
25.80 99.33 
25.80 99.76 
25.74 100.62 
25.95 100.62 
27.80 101.43 
24.51 104.49 
24.59 104.89 
25.51 105.78 
20.58 108.36 
21.64 119.97 
 
 
 
 
 
